Cerci, K. and Patir, P. 2023. Ruxolitinib as a therapy choice for refractory pruritus in a patient with essential thrombocythemia with CALR mutation. Global Journal of Medical and Clinical Case Reports. 10, 1 (Jan. 2023), 001–002. DOI:https://doi.org/10.17352/2455-5282.000167.